News

Fatima is attending the Westminster Health Forum Keynote Seminar tomorrow

The topic is ‘Payment Systems and Reimbursement in Healthcare’.

If you are in the area, or indeed attending the same event, please stop by to say hello and see how we can help you with your Pharmaceutical Pricing and Market Access requirements with payment systems and reimbursement within healthcare.

By |2020-01-17T14:31:00+00:00January 21st, 2020|News|Comments Off on Fatima is attending the Westminster Health Forum Keynote Seminar tomorrow

Remap Consulting are hiring!

Remap Consulting is a specialist pharmaceutical pricing and market access consultancy. We are growing, and looking for a Consultant to join our successful team. If you have an entrepreneurial spirit and a passion for pharmaceutical pricing and market access, enjoy working in a diverse team with no two days the same, then we would love to hear from you.

Click on the picture for further information:

By |2020-01-17T09:36:53+00:00January 17th, 2020|Careers, News|Comments Off on Remap Consulting are hiring!

Greater access to medicines in the UK? What does the NHS England Commercial Framework mean for manufacturers?

It is no secret that the NHS, like many other healthcare systems, is under increasing financial pressure. At the same time, the pharmaceutical industry is seeing the launch of increasing numbers of innovative medicines, often associated with price tags that create challenges of affordability and cost-effectiveness. Recognising this, NHS England is developing a new Commercial Framework, outlining potential opportunities for commercial flexibilities to enable patient access to innovative medicines whilst maintaining “value for money for taxpayers”.

Earlier this year, Remap Consulting wrote about the 2019 Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) agreement which, amongst other commitments, announced that NHS England would be developing and publishing the new Commercial Framework. In early November 2019, a draft version of this agreement was published for consultation.

The draft Framework summarises four potential commercial situations for manufacturers, as highlighted in Figure 1.

Figure 1 Commercial Options outlined in NHS England’s draft Commercial […]

By |2020-01-08T12:34:28+00:00January 8th, 2020|News|Comments Off on Greater access to medicines in the UK? What does the NHS England Commercial Framework mean for manufacturers?

NHS Commercial Framework Engagement Workshop

Fatima Chunara is attending the NHS Commercial Framework Engagement Workshop today (Wednesday 18th December) in Manchester.

She will then provide us with an update in the form of our December news article which we will publish this week.

By |2020-01-08T12:12:24+00:00December 18th, 2019|News|Comments Off on NHS Commercial Framework Engagement Workshop

Winners! Best New Investigator Podium Research Presentations

The team at Remap Consulting are delighted to announce that Fatima Chunara’s podium presentation ‘Is market access for oncology treatments easier in England than for non-oncology treatments?’ presented at ISPOR EU 2019 has been awarded Best New Investigator Podium Research Presentations.

Our research compared the outcomes of draft and final NICE outcomes and in the case of positive outcomes, the use of patient population restrictions and financial agreements for oncology and non-oncology drugs. Read our full findings here

We hope you will join us in congratulating Fatima for this fantastic achievement.

By |2019-12-16T14:17:23+00:00December 13th, 2019|News|Comments Off on Winners! Best New Investigator Podium Research Presentations

Should payers encourage further physician education and incentivisation to increase biosimilar uptake in the EU?

There are more than 45 biosimilars approved in Europe across a range of diseases in oncology, autoimmune disorders, diabetes and fertility[1]. The introduction of biosimilar antibodies, beginning with the approval of the first infliximab biosimilar in 2013, has been particularly game-changing due to their capacity to increase competition and significantly decrease the economic burden associated with autoimmune diseases such as rheumatoid arthritis.

By increasing competition, biosimilar medicines offer the potential for savings of up to €2 billion annually across the EU[2]. However, there is a high variation in biosimilar use and payer decision drivers across Europe, which may impact the savings that can be achieved through competition between originator biologics and biosimilars. For example, the uptake of infliximab biosimilars varied from ~90% in the UK to ~50% in France, Germany, and Spain in 2018[3].

Maximising the cost-saving potential of biosimilars remains a topic of much […]

By |2019-12-06T14:33:40+00:00December 6th, 2019|News|Comments Off on Should payers encourage further physician education and incentivisation to increase biosimilar uptake in the EU?

“We need to talk – when to get early scientific advice”

Graham recently provided his expert insights into an In Vivo article ‘We need to talk – when to get early scientific advice’.

Discussing the benefits of seeking early scientific advice and what companies need to take into consideration when planning for such advice. To find out more click here.

By |2019-11-20T11:25:14+00:00November 20th, 2019|News|Comments Off on “We need to talk – when to get early scientific advice”

Remap Consulting welcomes Alvaro San Martin to the team!

We are delighted to announce the appointment of Alvaro San Martin who will join the team at Remap Consulting as an Analyst.

Alvaro studied at the University of Manchester and has just finished his MSc in MS, Biotechnology and Enterprise. Alvaro also has an MSc in MS, Biochemistry: Recombinant Proteins and Biotechnology and a BSc (Hons) in Biochemistry, having gained a distinction in all three.

Outside of work, Alvaro’s main hobby is blacksmithing and he enjoys making custom made steel-work pieces.

We are sure Alvaro is going to settle in really well!

Alvaro San Martin

By |2019-11-18T08:13:02+00:00November 19th, 2019|News|Comments Off on Remap Consulting welcomes Alvaro San Martin to the team!